نتایج جستجو برای: sitagliptin phosphate

تعداد نتایج: 105931  

2012
Akira Kubota Hajime Maeda Akira Kanamori Kiyokazu Matoba Yasuyuki Jin Fuyuki Minagawa Mitsuo Obana Kotaro Iemitsu Shogo Ito Hikaru Amamiya Mizuki Kaneshiro Masahiko Takai Hideaki Kaneshige Kazuhiko Hoshino Masashi Ishikawa Nobuaki Minami Tetsuro Takuma Nobuo Sasai Sachio Aoyagi Takehiro Kawata Atsuko Mokubo Hiroshi Takeda Shin Honda Hideo Machimura Tetsuya Motomiya Manabu Waseda Yoshikazu Naka Yasushi Tanaka Yasuo Terauchi Ikuro Matsuba

UNLABELLED (J Diabetes Invest, doi: 10.1111/j.2040-1124.2012.00221.x, 2012) Aims/Introduction:  To determine the efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients after 3 months' therapy. MATERIALS AND METHODS   A retrospective, observational study of 741 type 2 diabetes patients was carried out; 110 received sitagliptin monotherapy, a...

2014
Qingwei Zhao Dongsheng Hong Dongsheng Zheng Yao Xiao Baohua Wu

BACKGROUND Sitagliptin is an important drug used for diabetes treatment and is used as a monotherapy in diabetic patients. However, there are also reported cases of diarrhea with sitagliptin use. Unfortunately, data concerning the relationship of diarrhea with sitagliptin use in various conditions have yet to be identified. Therefore, the overall incidence and risk of diarrhea with sitagliptin ...

Journal: :Journal of Bashir Institute of Health Sciences 2022

Background: Sitagliptin is a commonly used drug for the treatment of type 2 diabetes. Studies show that diabetic patients are at high risk suffering severe complications after amoebic infection. To treat these infections drugs like clarithromycin and metronidazole most indicated. Methods: were conducted in normal male Wistar rats with oral doses 10 mg/kg body weight sitagliptin, & 5 metroni...

2015
Dong-Yi Chen Szu-Heng Wang Chun-Tai Mao Ming-Lung Tsai Yu-Sheng Lin Feng-Chieh Su Chung-Chuan Chou Ming-Shien Wen Chun-Chieh Wang I-Chang Hsieh Kuo-Chun Hung Wen-Jin Cherng Tien-Hsing Chen Inyang Osemene.

The cerebrovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus (T2DM) with ischemic stroke remains uncertain. The aim of this study was to assess the efficacy and safety of sitagliptin in patients with T2DM with recent ischemic stroke. We analyzed data from the Taiwan National Health Insurance Research Database between March...

Journal: :The Journal of the Association of Physicians of India 2012
Swati Srivastava G N Saxena P Keshwani Ritesh Gupta

OBJECTIVE To compare the efficacy and safety of sitagliptin and glimepiride in treatment of patients with type 2 diabetes mellitus inadequately controlled with metformin alone. RESEARCH DESIGN AND METHODS In an 18 week, randomized parallel group interventional trial, 50 subjects who were only on metformin as antidiabetic agent, with inadequate glycemic control, were randomized to either sitag...

Journal: :The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique 2009
Elizabeth M Migoya Catherine H Stevens Arthur J Bergman Wen-lin Luo Kenneth C Lasseter Stacy C Dilzer Michael J Davies John A Wagner Gary A Herman

BACKGROUND Sitagliptin is a highly selective dipeptidyl peptidase-4 inhibitor for the treatment of patients with type 2 diabetes. Sitagliptin is primarily excreted by renal elimination as unchanged drug, with only a small percentage (approximately 16%) undergoing hepatic metabolism. OBJECTIVES The primary purpose of this study was to evaluate the influence of moderate hepatic insufficiency on...

Journal: :Journal of pharmacological sciences 2014
Shinji Takai Hiroshi Sakonjo Denan Jin

To clarify the role of dipeptidyl peptidase-4 (DPP-4) inhibition in vascular tissues, we compared the effects of the poorly tissue-penetrative DPP-4 inhibitor sitagliptin to the highly tissue-penetrative DPP-4 inhibitor linagliptin in Zucker diabetic fatty (ZDF) rats. Six-week-old ZDF rats were orally treated with placebo, sitagliptin (10 mg/kg), or linagliptin (3 mg/kg) for 4 weeks. Sitaglipti...

2015
Yumie Takeshita Toshinari Takamura Yuki Kita Akiko Takazakura Ken-ichiro Kato Yuki Isobe Shuichi Kaneko

PURPOSE We determined the feasibility of substituting sitagliptin or mitiglinide for bolus insulin injection therapy in patients with type 2 diabetes. METHODS 60 patients with type 2 diabetes were enrolled and randomized to switch from mealtime dosing of a rapid-acting insulin analog to either sitagliptin or mitiglinide for 16 weeks. RESULTS Body weight, body mass index, and waist circumfer...

2012
Ankur Kothari Sheetal Sharma

A simple and accurate method of analysis to determine Sitagliptin Phosphate (STG) and Simvastatin(SMV) in combined dosage forms was developed using simultaneous equation method at 267.0nm for Simvastatin and 238.0 nm for Simvastatin in spectra of their solutions in methanol: water(90:10). The calibration curves were linear [correlation coefficient (r) = 0.986 for STG and 0.998 for SMV] in conce...

Journal: :Clinical drug investigation 2011
James E Signorovitch Eric Q Wu Elyse Swallow Evan Kantor Liangyi Fan Jean-Bernard Gruenberger

BACKGROUND AND OBJECTIVE Vildagliptin and sitagliptin are oral dipeptidyl peptidase 4 inhibitors approved in Japan for the treatment of type 2 diabetes mellitus when adequate glycaemic control is not achieved with diet, exercise or sulphonylureas. The aim of this study was to compare 12-week glycaemic control with vildagliptin 50 mg twice daily versus sitagliptin 50 or 100 mg once daily in Japa...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید